Does MTHFR A1298C heterozygosity alone indicate clinically meaningful methylation impairment?

MTHFR A1298C heterozygosity is a common variant, not equivalent to rare severe MTHFR deficiency. For a 71-year-old man, genotype should not substitute for direct assessment of biochemical and clinical factors affecting homocysteine metabolism.

Clinical and biochemical evidence

• Human biomarker data found no significant A1298C genotype-associated differences in plasma homocysteine, folate, 5-methyltetrahydrofolate, vitamin B12, red-cell folate, or measured lymphocyte DNA-methylation and DNA-stability markers.
• Thus, an A1298C/AC result alone does not establish reduced methyl-group availability, impaired homocysteine remethylation, or clinically consequential “methylation impairment.”
• Professional guidance considers common MTHFR-polymorphism testing to have minimal clinical utility for thrombophilia, recurrent pregnancy loss, or testing relatives. Functional concerns should be assessed biochemically rather than inferred from this genotype.

Mechanistic interpretation

• MTHFR generates 5-methyltetrahydrofolate, a substrate for homocysteine remethylation. One review estimated MTHFR activity in A1298C heterozygotes at approximately 83% of the AA reference level.
• This modest activity difference is not a loss-of-function state and has not translated reliably into abnormal homocysteine, folate-related biomarkers, or measured DNA-methylation outcomes. A1298C alone is generally not associated with elevated plasma homocysteine.

Practical interpretation

• Plasma total homocysteine is an appropriate functional test when clinically indicated. An elevation supports investigation of disturbed one-carbon/homocysteine metabolism, but does not specifically implicate A1298C.
• Interpretation should include folate, vitamin B12 and, where relevant, vitamin B6, renal function, medications, thyroid status, smoking, alcohol exposure, and age-related contributors. Marked or persistent elevation warrants consideration of alternative or rare metabolic causes.

Bottom line

• A1298C heterozygosity alone should not be treated as evidence of clinically meaningful methylation dysfunction; direct biochemical corroboration—especially measured homocysteine, interpreted in clinical context—is required.